Abstract
Ample evidence indicates that glutamate homeostasis and neurotransmission are disrupted in major depressive disorder; but the nature of this disruption and the mechanisms by which it contributes to the syndrome are unclear. Likewise, the effect of existing antidepressants on glutamate is unclear, as is the potential of drugs directly targeting glutamatergic neurotransmission to act as novel antidepressant medications. These are areas of active research. Here we review current knowledge of the contribution of the NMDA receptor, one of the several types of glutamate receptor, to depression and its treatment. Several lines of evidence, in humans and in animal models, support the contention that neurotransmission via the NMDA receptor is dysregulated in depression. Drugs that target the NMDA receptor have shown antidepressant properties in both clinical and preclinical studies. Nevertheless, other effects of such medications, including both cognitive side effects and their psychotomimetic properties, complicate such an application and represent a challenge to the development of clinically useful agents.
Keywords: Metabotropic glutamate receptors, NR2A subunit gene, Ketamine, NMDA blockade, EAAT2 glutamate transporters
CNS & Neurological Disorders - Drug Targets
Title: The NMDA Receptor as a Therapeutic Target in Major Depressive Disorder
Volume: 6 Issue: 2
Author(s): Christopher Pittenger, Gerard Sanacora and John H. Krystal
Affiliation:
Keywords: Metabotropic glutamate receptors, NR2A subunit gene, Ketamine, NMDA blockade, EAAT2 glutamate transporters
Abstract: Ample evidence indicates that glutamate homeostasis and neurotransmission are disrupted in major depressive disorder; but the nature of this disruption and the mechanisms by which it contributes to the syndrome are unclear. Likewise, the effect of existing antidepressants on glutamate is unclear, as is the potential of drugs directly targeting glutamatergic neurotransmission to act as novel antidepressant medications. These are areas of active research. Here we review current knowledge of the contribution of the NMDA receptor, one of the several types of glutamate receptor, to depression and its treatment. Several lines of evidence, in humans and in animal models, support the contention that neurotransmission via the NMDA receptor is dysregulated in depression. Drugs that target the NMDA receptor have shown antidepressant properties in both clinical and preclinical studies. Nevertheless, other effects of such medications, including both cognitive side effects and their psychotomimetic properties, complicate such an application and represent a challenge to the development of clinically useful agents.
Export Options
About this article
Cite this article as:
Pittenger Christopher, Sanacora Gerard and Krystal H. John, The NMDA Receptor as a Therapeutic Target in Major Depressive Disorder, CNS & Neurological Disorders - Drug Targets 2007; 6 (2) . https://dx.doi.org/10.2174/187152707780363267
DOI https://dx.doi.org/10.2174/187152707780363267 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial (Thematic Issue: Induced Cell-Based Transplantation to Therapeutically Target Spinal Cord Disorders)
Current Stem Cell Research & Therapy The Interplay between G-quadruplex and Transcription
Current Medicinal Chemistry Exercise-Induced MicroRNA Regulation in the Mice Nervous System is Maintained After Activity Cessation
MicroRNA Current Progresses of Novel Natural Products and Their Derivatives/ Analogs as Anti-Alzheimer Candidates: an Update
Mini-Reviews in Medicinal Chemistry Coenzyme Q10 in Neuromuscular and Neurodegenerative Disorders
Current Drug Targets Tuning the Electronic Properties by Width and Length Modifications of Narrow- Diameter Carbon Nanotubes for Nanomedicine
Current Medicinal Chemistry Molecular Pathology in Neurodegenerative Diseases
Current Drug Targets Application of Sulfamic Acid in Organic Synthesis-A Short Review
Current Organic Chemistry Application of Stem Cell Therapy During the Treatment of HIV/AIDS and Duchenne Muscular Dystrophy
Current Stem Cell Research & Therapy 11C-verapamil to Assess P-gp Function in Human Brain During Aging,Depression and Neurodegenerative Disease
Current Topics in Medicinal Chemistry Targeting the Eph System with Peptides and Peptide Conjugates
Current Drug Targets Huntingtons Disease: The Value of Transcranial Meganetic Stimulation
Current Medicinal Chemistry Structural Properties of the NMDA Receptor and the Design of Neuroprotective Therapies
Mini-Reviews in Medicinal Chemistry MicroRNAs Involved in Oxidative Stress Processes Regulating Physiological and Pathological Responses
MicroRNA Mesenchymal Cells in the Treatment of Spinal Cord Injury: Current & Future Perspectives
Current Stem Cell Research & Therapy Nitric Oxide-GAPDH Transcriptional Signaling Mediates Behavioral Actions of Cocaine
CNS & Neurological Disorders - Drug Targets A New Interpretative Paradigm for Conformational Protein Diseases
Current Protein & Peptide Science Characterization of Adipose-Derived Stem Cells: An Update
Current Stem Cell Research & Therapy Application of Polymeric Nanoparticles for CNS Targeted Zinc Delivery In Vivo
CNS & Neurological Disorders - Drug Targets Neurotrophic Factors in the Pathogenesis of Neurological Disorders with Mental Retardation in Children
Current Pediatric Reviews